R Squared Ltd Invests $171,000 in McKesson Co. (NYSE:MCK)

R Squared Ltd purchased a new stake in McKesson Co. (NYSE:MCK) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 300 shares of the company’s stock, valued at approximately $171,000.

A number of other institutional investors have also recently bought and sold shares of MCK. Gateway Wealth Partners LLC purchased a new stake in McKesson during the fourth quarter valued at about $201,000. Patriot Financial Group Insurance Agency LLC lifted its position in shares of McKesson by 9.1% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 1,578 shares of the company’s stock valued at $899,000 after acquiring an additional 132 shares in the last quarter. Nilsine Partners LLC boosted its stake in McKesson by 5.7% in the 4th quarter. Nilsine Partners LLC now owns 4,450 shares of the company’s stock worth $2,536,000 after purchasing an additional 241 shares during the period. Foundations Investment Advisors LLC grew its position in McKesson by 21.3% during the 4th quarter. Foundations Investment Advisors LLC now owns 24,621 shares of the company’s stock worth $14,032,000 after purchasing an additional 4,320 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC raised its stake in McKesson by 14.2% during the 4th quarter. Mount Yale Investment Advisors LLC now owns 1,758 shares of the company’s stock valued at $1,002,000 after purchasing an additional 218 shares during the period. Hedge funds and other institutional investors own 85.07% of the company’s stock.

McKesson Stock Up 0.1 %

NYSE:MCK opened at $603.79 on Thursday. The company’s 50 day moving average is $592.16 and its 200-day moving average is $561.52. The firm has a market cap of $76.64 billion, a price-to-earnings ratio of 31.27, a P/E/G ratio of 1.26 and a beta of 0.52. McKesson Co. has a 12 month low of $464.42 and a 12 month high of $637.51.

McKesson (NYSE:MCK) last released its earnings results on Wednesday, November 6th. The company reported $7.07 earnings per share for the quarter, topping analysts’ consensus estimates of $6.88 by $0.19. The firm had revenue of $93.65 billion during the quarter, compared to analyst estimates of $89.33 billion. McKesson had a net margin of 0.77% and a negative return on equity of 207.50%. The business’s revenue was up 21.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $6.23 EPS. Research analysts predict that McKesson Co. will post 32.73 EPS for the current fiscal year.

Insider Buying and Selling at McKesson

In other news, EVP Leann B. Smith sold 579 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $572.79, for a total value of $331,645.41. Following the completion of the sale, the executive vice president now directly owns 864 shares of the company’s stock, valued at approximately $494,890.56. This represents a 40.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.11% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Baird R W upgraded McKesson from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 7th. Morgan Stanley upped their target price on McKesson from $612.00 to $642.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. Robert W. Baird raised shares of McKesson from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $531.00 to $688.00 in a research report on Thursday, November 7th. Bank of America cut their target price on shares of McKesson from $680.00 to $650.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Finally, Mizuho began coverage on shares of McKesson in a report on Wednesday, December 4th. They set a “neutral” rating and a $630.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, McKesson presently has a consensus rating of “Moderate Buy” and an average price target of $646.14.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.